European Journal of Pediatrics

, Volume 163, Issue 7, pp 402–407 | Cite as

l -5-Hydroxytryptophan treatment of sleep terrors in children

  • Oliviero BruniEmail author
  • Raffaele Ferri
  • Silvia Miano
  • Elisabetta Verrillo
Original Paper


To test the hypothesis that the administration of l -5-hydroxytryptophan ( l -5-HTP) might exert beneficial effects on sleep terrors, we carried out an open pharmacological trial in a group of children with sleep terrors compared to a group of children with the same disorder but without l -5-HTP treatment. Participants in the trial were 45 children (34 males and 11 females; age range 3.2–10.6 years), referred to the Sleep Centre of the Department of Developmental Neurology and Psychiatry of the University of Rome “La Sapienza”, affected by sleep terrors. All subjects underwent: (1) complete medical and sleep history; (2) complete neurological examination and EEG recording whilst awake and sleeping, (3) a structured sleep diary for 2 months, (4) after 1 month, all subjects were examined again from the clinical and EEG points of view and (5) after 6 months, a structured interview in order to evaluate the clinical outcome. After the first visit, l -5-HTP was administered (2 mg/kg per day) at bedtime to 31 randomly selected patients for a single period of 20 consecutive days. After 1 month of treatment, 29/31 (93.5%) of patients showed a positive response. In the comparison group without drug therapy, after 1 month, the episodes disappeared only in four children (28.6%) while ten children (71.4%) showed the persistence of episodes with the same frequency as before. After 6 months, 26/31 (83.9%) of children treated with l -5HTP were sleep terror-free, while in five children (16.1%) sleep terror episodes persisted. Of the children in the comparison group, ten (71.4%) continued to show sleep terrors at 6-month follow-up. Conclusion:to our knowledge, this is the first study demonstrating the efficacy of a new drug treatment for sleep terrors. These results confirm our initial hypothesis and represent evidence that treatment with l -5-hydroxytryptophan is able to modulate the arousal level in children and to induce a long-term improvement of sleep terrors.


Arousal disorders  l -5-Hydroxytryptophan Serotoninergic system Sleep terrors 



eosinophilia-myalgia syndrome


hypersynchronous high voltage delta waves arousal


high voltage monomorphic delta

l -5-HTP

l -5-hydroxytryptophan


non rapid eye movement


periodic limb movements during sleep


sleep-disordered breathing


  1. 1.
    Adrien J (1995) The serotoninergic system and sleep-wakefulness regulation. In: Kales A (ed) The pharmacology of sleep. Springer, Berlin Heidelberg New York, pp 91–116Google Scholar
  2. 2.
    American Sleep Disorders Association (1997) International classification of sleep disorders, revised: diagnostic and coding manual. American Sleep Disorders Association, Rochester, MinnesotaGoogle Scholar
  3. 3.
    Balon R (1994) Sleep terror disorder and insomnia treated with trazodone: a case report. Ann Clin Psychiatry 6: 161–163PubMedGoogle Scholar
  4. 4.
    Bastuji H, De Villard R, Garde P, Challamel MJ (1991) High voltage monomorphic delta activity during sleep in children with pavor nocturnus or somnambulism, and in normal controls. Sleep Res 20A: 285Google Scholar
  5. 5.
    Cameron OG, Thyer BA (1985) Treatment of pavor nocturnus with alprazolam. J Clin Psychiatry 46: 504Google Scholar
  6. 6.
    Dahl RE (1992) The pharmacologic treatment of sleep disorders. Psychiatric Clin North Am 15: 161–178Google Scholar
  7. 7.
    Daniels SR, Hudson JI, Horwitz RI (1995) Epidemiology of potential association between l -tryptophan ingestion and eosinophilia-myalgia syndrome. J Clin Epidemiol 48: 1413–1427CrossRefPubMedGoogle Scholar
  8. 8.
    De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S (1987) Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study - l -5-HTP versus placebo. Drugs Exp Clin Res 13: 425–433PubMedGoogle Scholar
  9. 9.
    DiMario FJ Jr, Emery ES III (1987) The natural history of sleep terrors. Clin Pediatr 26: 505–511Google Scholar
  10. 10.
    Driver H, Shapiro C (1993) Parasomnias. BMJ 306: 921–924PubMedGoogle Scholar
  11. 11.
    Espa F, Ondze B, Deglise P, Billiard M, Besset A (2000) Sleep architecture, slow wave activity, and sleep spindles in adult patients with sleepwalking and sleep terrors. Clin Neurophysiol 111: 929–939CrossRefPubMedGoogle Scholar
  12. 12.
    Farinelli S, Mariani A, Grimaldi A, Mariani M, Iannessi A, De Rosa F (1991) Eosinophilia-myalgia syndrome associated with 5-OH-tryptophan. Description of a case. Recenti Prog Med 82: 381–384PubMedGoogle Scholar
  13. 13.
    Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, de Rijk R, van der Post J, Cohen AF (2002) Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol 22: 183–189CrossRefPubMedGoogle Scholar
  14. 14.
    Guilleminault C, Palombini L, Pelayo R, Chervin RD (2003) Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics 111: e17–e25PubMedGoogle Scholar
  15. 15.
    Imeri L, Mancia M, Bianchi S, Opp MR (2000) 5-hydroxytryptophan, but not l -tryptophan, alters sleep and brain temperature in rats. Neuroscience 95: 445–452CrossRefPubMedGoogle Scholar
  16. 16.
    Jacos BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165–229PubMedGoogle Scholar
  17. 17.
    Kaufman J, Birmaher B, Perel J, Dahl RE, Stull S, Brent D, Trubnick L, Al-Shabbout M, Ryan ND (1998) Serotonergic functioning in depressed abused children: clinical and familial correlates. Biol Psychiatry 44: 973–981CrossRefPubMedGoogle Scholar
  18. 18.
    Klarskov K, Johnson KL, Benson LM, Cragun JD, Gleich GJ, Wrona M, Jiang X-R, Dryhurst G, Naylor S (2003) Structural characterization of a case-implicated contaminant, “peak x,” in commercial preparations of 5-hydroxytryptophan. J Rheumatol 30: 89–95PubMedGoogle Scholar
  19. 19.
    Kohen DP, Mahowald MW, Rosen GM (1992) Sleep-terror disorder in children: the role of self-hypnosis in management. Am J Clin Hypn 34:233–244PubMedGoogle Scholar
  20. 20.
    Lask B (1988) A novel and non-toxic treatment for sleep terrors. BMJ 297: 592Google Scholar
  21. 21.
    Michelson D, Page SW, Casey R, Trucksess MW, Love LA, Milstien S, Wilson C, Massaquoi SG, Crofford LJ, Hallett M et al (1994) An eosinophilia-myalgia syndrome related disorder associated with exposure to l -5-hydroxytryptophan. J Rheumatol 21: 2261–2265PubMedGoogle Scholar
  22. 22.
    Philen RM, Hill RH Jr, Flanders WD, Caudill SP, Needham L, Sewell L, Sampson EJ, Falk H, Kilbourne EM (1993) Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico. Am J Epidemiol 138: 154–159PubMedGoogle Scholar
  23. 23.
    Popoviciu L, Corfariu O (1983) Efficacy and safety of midazolam in the treatment of night terrors in children. Br J Clin Pharmacol 16[Suppl 1]: 97S–102SGoogle Scholar
  24. 24.
    Ramaekers VT, Senderek J, Haeusler M, Haering M, Abeling N, Zerres K, Bergmann C, Heimann G, Blau N (2001) A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa. Mol Genet Metab 73: 179–187CrossRefPubMedGoogle Scholar
  25. 25.
    Reimao R, Lefevre AB (1982) Evaluation of flurazepam and placebo on sleep disorders in childhood. Arq Neuropsiquiatr 40: 1-13PubMedGoogle Scholar
  26. 26.
    Ribeiro CA (2000) l -5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. For the Portuguese Head Society. Headache 40: 451–456CrossRefPubMedGoogle Scholar
  27. 27.
    Riemann D, Vorderholzer U (1998) Treatment of depression and sleep disorders. Significance of serotonin and l -tryptophan in pathophysiology and therapy. Fortschr Med 116: 40–42Google Scholar
  28. 28.
    Ryan ND, Birmaher B, Perel JM, Dahl RE, Meyer V, Al-Shabbout M, Iyengar S, Puig-Antich J (1992) Neuroendocrine response to l -5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry 49: 843–851PubMedGoogle Scholar
  29. 29.
    Schneider-Helmert D, Spinweber CL (1986) Evaluation of l -tryptophan for treatment of insomnia: a review. Psychopharmacology 89: 1–7PubMedGoogle Scholar
  30. 30.
    Schruers K, van Diest R, Nicolson N, Griez E (2002) l -5-Hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology 161: 365–369PubMedGoogle Scholar
  31. 31.
    Shapiro S (1996) Epidemiologic studies of the association of l -tryptophan with the eosinophilia-myalgia syndrome: a critique [see comments]. J Rheumatol Suppl 46: 44–58PubMedGoogle Scholar
  32. 32.
    Weissbluth M (1984) Is drug treatment of sleep terrors warranted? Am J Dis Child 138: 1086Google Scholar
  33. 33.
    Williamson BL, Klarskov K, Tomlinson AJ, Gleich GJ, Naylor S (1998) Problems with over-the-counter 5-hydroxy- l -tryptophan. Nat Med 4: 983CrossRefPubMedGoogle Scholar
  34. 34.
    Wyatt RJ, Engelamn K, Kupfer DJ, Fram DH, Sjoerdsma A and Snyder F (1970) Effects of l -tryptophan (a natural sedative) on human sleep. Lancet 7678: 842–845Google Scholar
  35. 35.
    Zucconi M, Oldani A, Ferini-Strambi L, Smirne S (1995) Arousal fluctuations in non-rapid eye movement parasomnias: the role of cyclic alternating pattern as a measure of sleep instability. J Clin Neurophysiol 12: 147–154PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Oliviero Bruni
    • 1
    Email author
  • Raffaele Ferri
    • 2
  • Silvia Miano
    • 2
  • Elisabetta Verrillo
    • 1
  1. 1.Centre for Paediatric Sleep Disorders, Department of Developmental Neurology and PsychiatryUniversity of Rome “La Sapienza”Rome Italy
  2. 2.Sleep Research Centre, Department of NeurologyOasi Institute for Research on Mental Retardation and Brain Aging (IRCCS)Troina Italy

Personalised recommendations